{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:09:05Z","timestamp":1774022945155,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Self-funded Research Project of Guangxi Zhuang Autonomous Region Health Commission","award":["Z-B20231448"],"award-info":[{"award-number":["Z-B20231448"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04616-x","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T03:46:57Z","timestamp":1770954417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global epidemiology and burden of multiple myeloma from 1990 to 2021 with projections to 2045 based on the global burden of disease study 2021"],"prefix":"10.1007","volume":"17","author":[{"given":"Haiyong","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjie","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puxiang","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qikai","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"11","key":"4616_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. MEDICAL PROGRESS multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360.","journal-title":"N Engl J Med"},{"issue":"5","key":"4616_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, et al. Diagnosis and management of multiple myeloma A review. Jama-Journal Am Med Association. 2022;327(5):464\u201377.","journal-title":"Jama-Journal Am Med Association"},{"issue":"3","key":"4616_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12(3):10.","journal-title":"Blood Cancer J"},{"issue":"12","key":"4616_CR4","doi-asserted-by":"publisher","first-page":"E538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):E538\u201348.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4616_CR5","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1172\/JCI129205","volume":"130","author":"SA Minnie","year":"2020","unstructured":"Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130(4):1565\u201375.","journal-title":"J Clin Invest"},{"issue":"6","key":"4616_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"Kyle RA, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121\u20137.","journal-title":"Leukemia"},{"issue":"8","key":"4616_CR7","doi-asserted-by":"publisher","first-page":"E328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):E328\u201346.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4616_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335\u201348.","journal-title":"Nat Rev Cancer"},{"key":"4616_CR9","first-page":"20","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, et al. Multiple myeloma. Nat Reviews Disease Primers. 2017;3:20.","journal-title":"Nat Reviews Disease Primers"},{"issue":"3","key":"4616_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol L, et al. Expert review on soft-tissue Plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021;194(3):496\u2013507.","journal-title":"Br J Haematol"},{"issue":"1","key":"4616_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","volume":"35","author":"H Ludwig","year":"2021","unstructured":"Ludwig H, et al. Recommendations for vaccination in multiple myeloma: a consensus of the European myeloma network. Leukemia. 2021;35(1):31\u201344.","journal-title":"Leukemia"},{"issue":"2","key":"4616_CR12","doi-asserted-by":"publisher","first-page":"E143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the international myeloma working group. Lancet Haematol. 2022;9(2):E143\u201361.","journal-title":"Lancet Haematol"},{"issue":"6","key":"4616_CR13","doi-asserted-by":"publisher","first-page":"e1003138","DOI":"10.1371\/journal.pmed.1003138","volume":"17","author":"X Cheng","year":"2020","unstructured":"Cheng X, et al. Population ageing and mortality during 1990\u20132017: A global decomposition analysis. PLoS Med. 2020;17(6):e1003138.","journal-title":"PLoS Med"},{"issue":"10292","key":"4616_CR14","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361\u201371.","journal-title":"Lancet"},{"issue":"1","key":"4616_CR15","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.1002\/onco.13569","volume":"26","author":"AA Khorana","year":"2021","unstructured":"Khorana AA, et al. Prediction and prevention of Cancer-Associated thromboembolism. Oncologist. 2021;26(1):E2\u20137.","journal-title":"Oncologist"},{"key":"4616_CR16","unstructured":"BrayF, et al. Technical publications. Planning and developing population-based cancer registration in low- or middle-income settings. International Agency for Research on Cancer; 2014. (IARC Technical Report, No. 43). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK566957\/"},{"issue":"1","key":"4616_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-023-00877-9","volume":"13","author":"MV Mateos","year":"2023","unstructured":"Mateos MV, et al. Global disparities in patients with multiple myeloma: a rapid evidence assessment. Blood Cancer J. 2023;13(1):109.","journal-title":"Blood Cancer J"},{"key":"4616_CR18","doi-asserted-by":"publisher","first-page":"978245","DOI":"10.3389\/fmed.2022.978245","volume":"9","author":"D Razzano","year":"2022","unstructured":"Razzano D, et al. The role of telepathology in improving cancer diagnostic and research capacity in sub-Saharan Africa. Front Med (Lausanne). 2022;9:978245.","journal-title":"Front Med (Lausanne)"},{"key":"4616_CR19","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1200\/GO.21.00249","volume":"7","author":"K Yadav","year":"2021","unstructured":"Yadav K, et al. Telemedicine and cancer care in Low- and Middle-Income countries during the SARS-CoV-2 pandemic. JCO Glob Oncol. 2021;7:1633\u20138.","journal-title":"JCO Glob Oncol"},{"issue":"1","key":"4616_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.46989\/001c.92555","volume":"6","author":"M Mattar","year":"2024","unstructured":"Mattar M, et al. Epidemiology, treatment Trends, and outcomes of multiple myeloma in the middle East and africa: A systematic review. Clin Hematol Int. 2024;6(1):67\u201383.","journal-title":"Clin Hematol Int"},{"issue":"1","key":"4616_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-023-00849-z","volume":"13","author":"J El-Cheikh","year":"2023","unstructured":"El-Cheikh J, et al. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies. Blood Cancer J. 2023;13(1):10.","journal-title":"Blood Cancer J"},{"issue":"2","key":"4616_CR22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11357-022-00698-x","volume":"45","author":"VS Urban","year":"2023","unstructured":"Urban VS, Cegledi A, Mikala G. Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment. Geroscience. 2023;45(2):727\u201346.","journal-title":"Geroscience"},{"issue":"3","key":"4616_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41375-021-01506-9","volume":"36","author":"J Caro","year":"2022","unstructured":"Caro J, et al. Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. Leukemia. 2022;36(3):613\u201324.","journal-title":"Leukemia"},{"key":"4616_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2023.02.008","volume":"91","author":"EA Larson","year":"2023","unstructured":"Larson EA, Dalamaga M, Magkos F. The role of exercise in obesity-related cancers: current evidence and biological mechanisms. Sem Cancer Biol. 2023;91:16\u201326.","journal-title":"Sem Cancer Biol"},{"key":"4616_CR25","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.26512","volume":"97","author":"U Goel","year":"2022","unstructured":"Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022;97:S3\u201325.","journal-title":"Am J Hematol"},{"issue":"3","key":"4616_CR26","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/1878-0261.12772","volume":"15","author":"CM Friedenreich","year":"2021","unstructured":"Friedenreich CM, Ryder-Burbidge C, McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol Oncol. 2021;15(3):790\u2013800.","journal-title":"Mol Oncol"},{"issue":"1","key":"4616_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"LH Zhou","year":"2021","unstructured":"Zhou LH, et al. Measuring the global, regional, and National burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21(1):13.","journal-title":"BMC Cancer"},{"key":"4616_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canep.2021.102072","volume":"76","author":"B White","year":"2022","unstructured":"White B, et al. Does changing healthcare use signal opportunities for earlier detection of cancer? A review of studies using information from electronic patient records. Cancer Epidemiol. 2022;76:8.","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"4616_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2217\/fon-2020-1003","volume":"17","author":"D Madduri","year":"2021","unstructured":"Madduri D, et al. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the united States. Future Oncol. 2021;17(5):503\u201315.","journal-title":"Future Oncol"},{"issue":"12","key":"4616_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/cancers13123053","volume":"13","author":"C DuMontier","year":"2021","unstructured":"DuMontier C, et al. Contemporary analysis of electronic frailty measurement in older adults with multiple myeloma treated in the National US veterans affairs healthcare system. Cancers. 2021;13(12):18.","journal-title":"Cancers"},{"issue":"1","key":"4616_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, et al. Multiple Myeloma, version 3.2022\u2009<\u2009i>Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2022;20(1):9\u201319.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"4616_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41467-020-15740-9","volume":"11","author":"EH Rustad","year":"2020","unstructured":"Rustad EH, et al. Timing the initiation of multiple myeloma. Nat Commun. 2020;11(1):14.","journal-title":"Nat Commun"},{"issue":"6","key":"4616_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/ijms23063112","volume":"23","author":"YC Gau","year":"2022","unstructured":"Gau YC, et al. Pathogenesis and treatment of Myeloma-Related bone disease. Int J Mol Sci. 2022;23(6):18.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4616_CR34","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107.","journal-title":"Am J Hematol"},{"issue":"9","key":"4616_CR35","doi-asserted-by":"publisher","first-page":"E670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"JJ Huang","year":"2022","unstructured":"Huang JJ, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and Temporal trends. Lancet Haematol. 2022;9(9):E670\u20137.","journal-title":"Lancet Haematol"},{"issue":"2","key":"4616_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41408-020-0284-7","volume":"10","author":"CR Marinac","year":"2020","unstructured":"Marinac CR, et al. Dissecting Racial disparities in multiple myeloma. Blood Cancer J. 2020;10(2):8.","journal-title":"Blood Cancer J"},{"issue":"10","key":"4616_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/jcm9103277","volume":"9","author":"JL Nicol","year":"2020","unstructured":"Nicol JL, et al. Physical activity in people with multiple myeloma: associated factors and exercise program preferences. J Clin Med. 2020;9(10):11.","journal-title":"J Clin Med"},{"issue":"4","key":"4616_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1200\/JOP.19.00309","volume":"16","author":"V Kumar","year":"2020","unstructured":"Kumar V, et al. Timeliness of initial therapy in multiple myeloma: trends and factors affecting patient care. Jco Oncol Pract. 2020;16(4):168\u2013.","journal-title":"Jco Oncol Pract"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04616-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04616-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04616-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:19:35Z","timestamp":1774019975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04616-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4616"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04616-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study relied on publicly accessible summary statistics from previously published research and consortia. Each original study involved in this research had received ethical clearance from their respective review boards, and all participants had given informed consent. Notably, this research did not involve the use of individual-level data, thereby eliminating the need for new ethical review board approval. Not applicable. This study utilized publicly available, anonymized data from the GBD 2021 database and did not involve direct participation of human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}